Lv61
1970 积分 2021-06-21 加入
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
12天前
已完结
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
12天前
已完结
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
12天前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
14天前
已完结
Cancer therapy with antibodies
14天前
已完结
Antibody–drug conjugates come of age in oncology
14天前
已完结
Claudin 18.2 as a novel therapeutic target
14天前
已完结
支气管哮喘防治指南（2024年版）
3个月前
已完结
皖公网安备34019202002308
